Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Short Interest Update

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) was the target of a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 40 shares, a decline of 67.5% from the May 14th total of 123 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 53 shares, the days-to-cover ratio is currently 0.8 days.

Orion OYJ Stock Performance

OTCMKTS:ORINY opened at $37.99 on Thursday. The company has a market capitalization of $10.72 billion, a PE ratio of 17.43 and a beta of 0.08. The company has a quick ratio of 1.13, a current ratio of 1.77 and a debt-to-equity ratio of 0.10. Orion OYJ has a 52-week low of $25.95 and a 52-week high of $42.75. The stock has a fifty day simple moving average of $37.99 and a 200-day simple moving average of $37.96.

Orion OYJ (OTCMKTS:ORINY) last released its quarterly earnings results on Thursday, April 23rd. The company reported $0.37 earnings per share (EPS) for the quarter. Orion OYJ had a return on equity of 49.17% and a net margin of 27.14%.The business had revenue of $488.80 million during the quarter.

About Orion OYJ

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.